A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Amcasertib (Primary) ; Napabucasin (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boston Biomedical
- 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 06 Jun 2017 Results (n=20) from phase I part of the trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 03 Jun 2017 Interim results (n=27) presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Boston Biomedical media release.